Search clinical trials for: CTP-543 BID Dose Regimen

Total 698 results

Oblato, Inc.

Recruiting

Study of Safety and Pharmacokinetic Properties of Oral OKN-007 in Patients With Recurrent High-Grade Glioma

Astrocytoma | Glioblastoma Multiforme | Oligodendroglioma | High-grade Glioma

United States
Concert Pharmaceuticals

Completed

Efficacy and Tolerability Study of Two Dose Regimens of CTP-543 in Adults With Alopecia Areata

Alopecia Areata

United States
Concert Pharmaceuticals

Completed

Study to Evaluate the Safety and Efficacy of CTP-543 in Adults With Moderate to Severe Alopecia Areata

Alopecia Areata

United States
Concert Pharmaceuticals

Completed

Efficacy and Tolerability Study of Two Dosing Regimens of CTP-543 in Adults With Alopecia Areata

Alopecia Areata

United States, Canada
Concert Pharmaceuticals

Completed

Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CTP-543 in Healthy Subjects

Healthy

Australia
Concert Pharmaceuticals

Completed

Study to Evaluate the Efficacy and Safety of CTP-543 in Adults With Moderate to Severe Alopecia Areata (THRIVE-AA2) (THRIVE-AA2)

Alopecia Areata

Spain, United States, Poland, Canada, France, Germany, Hungary
Concert Pharmaceuticals

Completed

Study to Evaluate the Efficacy and Safety of CTP-543 in Adults With Moderate to Severe Alopecia Areata (THRIVE-AA1) (THRIVE-AA1)

Alopecia Areata

United States, Canada, Poland, France, Spain
Concert Pharmaceuticals

Enrolling by invitation

Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata

Alopecia Areata

United States, Canada
Concert Pharmaceuticals

Active, not recruiting

European Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata

Alopecia Areata

Spain, Germany, Poland, France, Hungary
Concert Pharmaceuticals

Completed

Study to Assess the Effect of Renal Impairment on the Pharmacokinetics of CTP-543

Renal Impairment

United States
Concert Pharmaceuticals

Completed

Food Effect Study of CTP-543 in Healthy Volunteers

Healthy

United States
Concert Pharmaceuticals

Completed

Study to Assess the Effect of Hepatic Impairment on the Pharmacokinetics of CTP-543

Hepatic Impairment

United States
Concert Pharmaceuticals

Completed

Study of the Effect of Food on the Bioavailability of the To-Be-Marketed Formulation of CTP-543 in Healthy Volunteers

Health Volunteers

United States
Concert Pharmaceuticals

Completed

A Study to Evaluate the Durability of Response Study of CTP-543 in Adult Patients With Moderate to Severe Alopecia Areata

Alopecia Areata

United States
Aclaris Therapeutics, Inc.

Completed

ATI-501 Oral Suspension Compared to Placebo in Subjects With Alopecia Areata, Alopecia Universalis or Alopecia Totalis

Alopecia

United States
Teva Branded Pharmaceutical Products R&D, Inc.

Recruiting

A Study to Evaluate the Long-Term Effect of TEV-48574 in Moderate to Severe Ulcerative Colitis or Crohn's Disease

Crohn Disease | Colitis, Ulcerative

United States, Hungary, Poland, Czechia, Japan, Belgium, Spain, Bulgaria, France, Italy, Slovakia, Austria
Chiesi Farmaceutici S.p.A.

Completed

Phase II Study to Evaluate the Cardiac Safety of 2 Doses of CHF5993 Both Combined With CHF1535 BID Versus CHF1535 BID in Patients With Moderate to Severe COPD (CARSAF)

Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

Bulgaria, Germany, Hungary, Poland, Russian Federation, United Kingdom
Concert Pharmaceuticals
Celerion

Completed

Study Evaluating Pharmacokinetics and Mass Balance of [14C]-CTP-543 in Healthy Adult Male Volunteers

Healthy Volunteers

United States
Concert Pharmaceuticals

Completed

Drug-drug Interaction Study of CTP-543 and Rifampin in Healthy Adult Subjects

Healthy Volunteers

United States
Concert Pharmaceuticals

Completed

Drug-drug Interaction Study of CTP-543 and Itraconazole in Healthy Adult Subjects

Healthy Volunteers

United States
Sun Pharma Advanced Research Company Limited

Completed

Safety Study of SPARC1104

Spasticity

United States
Concert Pharmaceuticals

Completed

Open-Label Crossover Study Comparing CTP-543 to Jakafi®

Healthy

United States
Galapagos NV

Completed

A Study Looking at the Safety, Tolerability and Efficacy of the Combination of the Study Drugs GLPG2451 and GLPG2222 With or Without GLPG2737 in Patients With Cystic Fibrosis. (FALCON)

Cystic Fibrosis

Belgium, Bulgaria, Germany, Greece, Netherlands, Serbia, Sweden, United Kingdom
Mercy Medical Center

Recruiting

Comparison Between 2-dose Versus 3-dose Regimens of Heplisav B in Cirrhosis

Hepatitis B | Cirrhosis, Liver | Chronic Liver Disease

United States
Serum Institute of India Pvt. Ltd.
Bill and Melinda Gates Foundation

Not yet recruiting

Clinical Study to Evaluate SIIPL qHPV Vaccine (CERVAVAC®) in Women Living With HIV Aged 15-25 Years

Human Papillomavirus Infection

Kenya, Mozambique, South Africa
Sinovac Biotech Co., Ltd

Completed

Studies of the Safety and Immunogenicity of a Sabin Inactivated Poliovirus Vaccine

Poliomyelitis

China
Reistone Biopharma Company Limited

Terminated

Assess the Efficacy and Safety of SHR0302 Ointment in Adult Patients With Vitiligo

Vitiligo

China
Jiangsu Province Centers for Disease Control and...
West China Hospital

Completed

A Phase Ⅱ Clinical Trial of Recombinant Corona Virus Disease-19 (COVID-19) Vaccine (Sf9 Cells)

COVID-19

China
University of Oxford

Completed

Adjuvanting Viral Vectored Malaria Vaccines With Matrix M

Malaria | Matrix M

United Kingdom
Jiangsu Province Centers for Disease Control and...
Beijing Minhai Biotechnology Co., Ltd

Completed

Safety and Immunogenicity of a Sabin Inactivated Poliovirus Vaccine.

Polio and Post-Polio Syndrome

China
Beacon Therapeutics

Enrolling by invitation

A Study Comparing Two Doses of AGTC-501 in Male Participants With X-linked Retinitis Pigmentosa Caused by RPGR Mutations (DAWN)

X-Linked Retinitis Pigmentosa

United States
The First Affiliated Hospital of Soochow University

Unknown

Idarubicin Plus Cytarabine (IA) vs IA Plus Cladribine (IAC) as Induction Regimen to Treat Initially Diagnosed Acute Myeloid Leukemia (AML)

Acute Myeloid Leukemia

China
Chong Kun Dang Pharmaceutical

Completed

The Parallel Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of CKD-843 A

Alopecia

Korea, Republic of
Biocad

Completed

Study of the Pharmacodynamics, Pharmacokinetics, Safety, and Immunogenicity of Single Escalating Doses of BCD-180 in Healthy Volunteers

Healthy

Russian Federation
BioMed Valley Discoveries, Inc

Completed

Phase I Dose-Escalation, Safety, Pharmacokinetic and Pharmacodynamic Study of BVD-523 in Patients With Advanced Malignancies

Advanced Solid Tumors

United States
BioMed Valley Discoveries, Inc

Completed

Phase 1/2 Study of the ERK1/2 Inhibitor BVD-523 in Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndromes

Myelodysplastic Syndrome | Acute Myelogenous Leukemia

United States
Arcturus Therapeutics, Inc.

Completed

Ascending Dose Study of Investigational SARS-CoV-2 Vaccine ARCT-021 in Healthy Adult Subjects

SARS-CoV-2

Singapore
Alladapt Immunotherapeutics, Inc.

Completed

ADP101 for Oral Immunotherapy in Food-Allergic Children and Adults

Food Allergy

United States
Enanta Pharmaceuticals, Inc
hVIVO Services Limited

Recruiting

A Controlled Phase 2a Study to Evaluate the Efficacy of EDP-323 Against Respiratory Syncytial Virus Infection in a Virus Challenge Model

RSV Infection

United Kingdom
Boehringer Ingelheim
Eli Lilly and Company

Completed

Safety and Efficacy Study of Empagliflozin and Metformin for 24 Weeks in Treatment Naive Patients With Type 2 Diabetes

Hyperglycemia | Diabetes Mellitus, Type 2

United States, Brazil, Canada, Czech Republic, Egypt, France, Germany, Guatemala, Korea, Republic of, Lebanon, Malaysia, Mexico, Peru, Philippines, Russian Federation, Serbia, Spain, Taiwan, Thailand, Turkey, United Kingdom
Dana-Farber Cancer Institute
BioMed Valley Discoveries, Inc

Active, not recruiting

A Phase II Study of BVD-523 in Metastatic Uveal Melanoma

Uveal Melanoma

United States
xCures
Cancer Commons

Available

Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies

Melanoma | Head and Neck Cancer | Glioblastoma | Hepatocellular Carcinoma | Gastric Cancer | Colorectal Cancer | Pancreatic Cancer | Esophageal Cancer | Small Bowel Cancer | Ovarian Cancer | Non Small Cell Lung Cancer | Cholangiocarcinoma | Bladder Cancer | Thyroid Cancer | ERK Mutation | MAPK Gene Mutation | KRAS Activating... and other conditions

United States
Bial - Portela C S.A.

Completed

Absorption, Distribution, Metabolism and Excretion of [14C]- Labeled BIA 5-453 and Metabolites

Hypertension | Congestive Heart Failure

Switzerland
Mitsubishi Tanabe Pharma Corporation

Completed

Efficacy and Safety of MP-513 in Combination With Metformin in Patients With Type 2 Diabetes

Type 2 Diabetes Mellitus

Poland, United Kingdom, Germany, Romania, Hungary, Denmark, Lithuania
BioMed Valley Discoveries, Inc

Completed

Absorption, Metabolism and Excretion (AME) of Single Dose Radiolabeled BVD-523 in Volunteers

Healthy
Bial - Portela C S.A.

Completed

Pharmacokinetics of BIA 5-453 and Its Metabolites

Hypertension | Chronic Heart Failure

France
Bial - Portela C S.A.

Completed

Bioavailability Study of BIA 5-453

Hypertension | Congestive Heart Failure

France
Janssen Research & Development, LLC

Suspended

A Study of JNJ-64281802 Against Dengue Serotype 1 Infection in a Dengue Human Challenge Model in Healthy Adult Participants

Healthy

United States, United Kingdom
Mingzhi Zhang

Unknown

Treatment of Elderly Patients With Diffuse Large B-cell Lymphoma

Diffuse Large B Cell Lymphoma

China
CTI BioPharma
PPD

Recruiting

Study to Evaluate the Safety, Tolerability, and PK of Pacritinib

Hepatic Impairment

United States

Search clinical trials for: CTP-543 BID Dose Regimen

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Peru

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations